<DOC>
	<DOCNO>NCT02047097</DOCNO>
	<brief_summary>The primary objective study determine incidence , type , pattern serious adverse event ( SAEs ) , include limited infection ( include opportunistic infection ) , hepatic event , malignancy , renal event , adverse event ( AEs ) lead treatment discontinuation patient MS treat dimethyl fumarate ( DMF ) . Secondary objective study population follow : To determine dimethyl fumarate ( DMF ) prescription utilization pattern routine clinical practice patient multiple sclerosis ( MS ) ; To assess effectiveness dimethyl fumarate ( DMF ) multiple sclerosis ( MS ) disease activity disability progression routine clinical practice determine Expanded Disability Status Scale ( EDSS ) score multiple sclerosis ( MS ) relapse information ; To assess effect dimethyl fumarate ( DMF ) health-related quality life , healthcare resource consumption , work productivity .</brief_summary>
	<brief_title>Dimethyl Fumarate ( DMF ) Observational Study</brief_title>
	<detailed_description>Patients age 12 18 may include enrollment pediatric patient study consider observational permissible local regulation .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Patients multiple sclerosis ( MS ) newly initiate treatment dimethyl fumarate ( DMF ) routine clinical care eligible participate study . Key Patients previous exposure dimethyl fumarate ( DMF ) , Fumaderm ( fumaric acid ester ) , compound fumarates . Patients participate clinical study . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>